Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc (ACAD) today and set a price target of $40. The company’s shares closed yesterday at $23.66.
According to TipRanks.com, Carr is a 4-star analyst with an average return of 4.6% and a 43.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
ACADIA Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.67, which is a 67.7% upside from current levels. In a report issued on April 25, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.67 and a one-year low of $12.77. Currently, ACADIA Pharmaceuticals Inc has an average volume of 1.37M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment.
